REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Estradiol (Primary) ; Polycarbophil (Primary)
- Indications Atrophic vaginitis
- Focus Therapeutic Use
- Acronyms REVIVE
- 31 Jan 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2020.
- 31 Jan 2019 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated